AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2005
(Rupees inLacs)
STANDALONE
CONSOLIDATED
Nine Months
Three months
Three months
Year
Year
Year
Year
PARTICULARS
ended
ended
ended
ended
ended
ended
ended
31.12.2004
31.03.2005
31.03.2004
31.03.2005
31.3.2004
31.03.2005
31.3.2004
Unaudited
Audited
Audited
Audited
Audited
Audited
Audited
Net Sales/Operational Income
15622.73
8322.20
4522.28
23944.93
16652.16
23954.21
16652.16
Others Income
35.36
22.14
121.74
57.50
193.11
57.50
193.11
Total Expenditure :
12458.68
7124.08
4012.47
19582.77
14688.67
19671.49
14688.67
a)(Increase)/decrease in stock in trade
-1227.46
294.66
-24.25
-932.80
-675.87
-932.80
-675.87
b) Consumption of Raw Material
10654.27
5646.36
3115.51
16300.63
12256.41
16300.63
12256.41
c) Staff Cost
293.68
148.14
68.95
441.83
245.21
483.37
245.21
d) Other expenditure
2738.19
1034.92
852.26
3773.11
2862.92
3820.29
2862.92
Interest
584.14
246.40
193.16
830.54
708.31
830.54
708.31
Depreciation
286.84
123.01
79.84
409.85
278.67
412.68
278.67
Profit(+)/Loss(-) before tax
2328.42
850.85
358.56
3179.27
1169.62
3097.00
1169.62
Provision for taxation
194.64
65.63
16.15
260.27
75.48
260.27
75.48
Net Profit/Loss before Deferred Tax
2133.78
785.22
342.41
2919.00
1094.14
2836.73
1094.14
Provision for deferred tax
392.46
-121.42
167.43
271.04
324.98
271.04
324.98
Net Profit/Loss
1741.32
906.64
174.99
2647.96
769.17
2565.70
769.17
Provision for Dividend on Preference Shares
3.51
3.51
3.51
3.51
3.51
Provision for Pref. Dividend Tax
0.45
0.46
0.45
0.46
0.45
Retained Profit
1741.32
906.64
171.03
2644.00
765.21
2561.73
765.21
Provision for dividend on Equity Shares
245.20
156.13
245.20
156.13
Provision for Equity dividend tax
32.04
20.01
32.04
20.01
Transfer to General Reserve
198.30
76.92
198.30
76.92
Retained Profit
2168.46
512.16
2086.19
512.16
Paid up Equity Share Capital
1840.00
1561.37
1840.00
1561.37
Reserve excluding revaluation reserves
8874.14
3581.75
8791.88
3581.75
EPS Rs.
Basic
11.03
5.15
1.17
16.17
5.24
15.67
5.24
Diluted
10.31
5.32
1.09
15.64
4.87
15.15
4.87
Aggregated on Non-Promoters
Shareholding
No. of Shares
13004594
9779594
13004594
9779594
% of Shareholding
70.68%
62.63%
70.68%
62.63%
Notes:
a) During the FY 2004-05, the turnover increased
by 43.79% and the net profit increased by 244.26% as compared to corresponding figures
of the previous year. The Exports during the financial year also saw a jump of 60.18%.
b) During the Quarter ended March, 05 the turnover
increased by 84.03% and net profit increased by 418.12%. The Exports during the
quarter increased by 61.95%.
c) The Company’s expansion plan where
it is setting up new facilities and undergoing capacity expansion is at advanced
stages of completion. The low volume High value facility is already operational.
d) The Board has recommended a dividend of 15%
for the FY 2004-05
e) The Consolidated financial results for the
period under consideration represents consolidated first year results of the wholly
owned subsidiary of the Company in US as per AS – 21 issued by ICAI.
f) 16 Complaints were received during the quarter,
out of which all complaints were duly redressed to the satisfaction of Shareholders.
g) The previous period figures have been re-grouped
and re-arranged wherever necessary.
i) The company is exclusively in the Pharmaceutical
business segment.
j) The above results were taken on record by
the board of directors in its meeting held on 13th June 2005.
